3-Aminobenzamide

3-Aminobenzamide

SCHEMBL16070

NC(=O)c1cccc(N)c1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.63
PARP1 P09874 9/20 0.61
F2 P00734 1/20 0.59
PLG P00747 1/20 0.59
PRSS1 P07477 1/20 0.59
PRSS2 P07478 1/20 0.59
PRSS3 P35030 1/20 0.59
POLB P06746 2/20 0.54
TSHR P16473 2/20 0.54
CYP3A4 P08684 2/20 0.54
RECQL P46063 2/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPT P10636 1/20 0.54
CYP2C19 P33261 1/20 0.54
BLM P54132 1/20 0.54
PMP22 Q01453 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
NPC1 O15118 1/20 0.53
MITF O75030 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
3-Aminobenzamide SCHEMBL27679552 1.00 PBRM1 (0.63) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL8688920 0.98 F2 (0.63) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL28015741 0.98 PBRM1 (0.61) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL28944114 0.98 PBRM1 (0.61) PBRM1PARP1F2PLGPRSS1
SCHEMBL2909580 0.93 PARP1 (0.59) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL28759683 0.92 PBRM1 (0.60) PBRM1PARP1F2PLGPRSS1
Terephthalic Acid SCHEMBL28053568 0.90 PBRM1 (0.58) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL27579659 0.88 PARP1 (0.81) PBRM1PARP1F2PLGPRSS1
SCHEMBL3790485 0.87 ERN1 (0.54) PBRM1PARP1F2PLGPRSS1
3-Aminobenzamide SCHEMBL10277410 0.87 PBRM1 (0.55) PBRM1PARP1F2PLGPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6656 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3594323-B1 METHODS AND COMPOSITIONS FOR GENERATING PANCREATIC PROGENITORS AND FUNCTIONAL BETA CELLS FROM HPSCS UNIV HEALTH NETWORK (CA) 2026-05-27 EP claimed
US-12637510-B2 Oncolytic virus compositions and methods for the treatment of cancer CITY OF HOPE (US) 2026-05-26 US claimed
EP-4739310-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-05-13 EP claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
US-20260027126-A1 COMBINATION THERAPY FOR TREATING CANCERS GEISTLICH PHARMA AG (CH) 2026-01-29 US claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
US-20250340879-A1 COMPOSITIONS AND METHODS FOR NUCLEIC ACID TRANSFER CHILDRENS HOSPITAL MED CT (US) 2025-11-06 US claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
US-5516941-A OXIDIZING 3-AMINOBENZAMIDE TO 3-NITROSOBENZAMIDE; VIRICIDES; ANTICARCINOGENIC AND ANTITUMOR AGENTS OCTAMER, INC. (US) 1996-05-14 US claimed
WO-1995034680-A1 METHOD TO IDENTIFY TUMOR SUPPRESSOR GENES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1995-12-21 WO claimed
EP-0672250-A1 A NOVEL $i(IN VITRO) METHOD OF SCREENING POTENTIAL ANTICANCER DRUGS USING A CELL DIFFERENTIATION ASSAY PROCYON BIOPHARMA INC. (CA) 1995-09-20 EP claimed
EP-0612240-A4 METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS. LONG DAVID M JR (US) 1995-05-17 EP claimed
EP-0612240-A1 METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS Long, David M., Jr. (US) 1994-08-31 EP claimed
WO-1994000758-A1 A NOVEL IN VITRO METHOD OF SCREENING POTENTIAL ANTICANCER DRUGS USING A CELL DIFFERENTIATION ASSAY VETROGEN CORPORATION (CA) 1994-01-06 WO claimed
WO-1993009762-A2 METHOD FOR EXTENDING THE VASCULAR DWELL-TIME OF PARTICULATE THERAPEUTIC AND PARTICULATE DIAGNOSTIC AGENTS LONG DAVID M JR (US) 1993-05-27 WO claimed
EP-0531370-A1 INHIBITION OF VIRAL INFECTION. COLLINS MARY KATHARINE LEVINGE (GB) 1993-03-17 EP claimed
WO-1991018591-A1 INHIBITION OF VIRAL INFECTION COLLINS MARY KATHARINE LEVINGE (GB) 1991-12-12 WO claimed
US-4970297-A CONTAINING ISOXAZOLE RING SYNTEX (U.S.A.) INC. (US) 1990-11-13 US claimed